FLT3 Gene Mutation Quantitative Monitoring Test in UAE | 650 AED

Executive Summary & Core Metrics

Advanced quantitative FLT3 mutation assay with DHA accreditation – 99.9% diagnostic sensitivity for acute myeloid leukemia monitoring and therapeutic decision support.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by DHA-licensed physicians.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The FLT3 quantitative monitoring test precisely measures the variant allele frequency of FLT3-ITD and tyrosine kinase domain mutations in peripheral blood or bone marrow of leukemia patients, essential for assessing minimal residual disease and guiding tyrosine kinase inhibitor therapy. This highly sensitive assay detects and quantifies abnormal gene copies, enabling your oncologist to track response and detect early relapse. The test uses real‑time PCR with allelic discrimination, cross‑validated by whole genome sequencing, achieving a sensitivity of 0.01% mutant allele in wild‑type background.

Feature	Our Test (DHA-Certified)	Closest Alternative
Methodology	Real‑Time PCR (qPCR) with allelic discrimination, cross‑validated by WGS	Sanger sequencing or single‑gene PCR
Sensitivity	0.01% mutant allele in wild‑type background (ISO‑verified)	~1‑5% (may miss low‑level MRD)
Turnaround Time	Sample Mon/Thu by 11 AM – Report Wed/Sat	7‑10 working days
Pre‑test Requirement	MRD Requisition Form (Form 22) with historical data	Often missing dedicated MRD protocol

Physician Insight & Safety Protocols

“As a Consultant in Medical Genetics, I understand the anxiety that accompanies FLT3 monitoring. This quantitative assay is a vital tool, but it must always be interpreted within the full clinical picture—a rise in mutation burden does not automatically mean treatment failure. Please continue your prescribed medication and consult your hematologist before any modification.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication & Clinical Guidance

Do not discontinue or alter prescribed medication (especially FLT3 inhibitors) without consulting your treating physician. The FLT3 quantitative monitoring test is an adjunctive tool for therapy response assessment and should never replace comprehensive clinical evaluation.

Exclusion Criteria & Emergency Red Flags

Do not proceed with home collection if the patient has active high fever (>38.5°C), uncontrolled bleeding, or suspected tumor lysis syndrome – escalate to ER immediately.
Bone marrow aspirate is excluded in patients with uncorrected severe coagulopathy or infection at the aspiration site.
Minors require a legal guardian’s consent per Federal Law No. 3 of 2016 (Child Rights) and DHA policy.
If the patient experiences sudden bruising, petechiae, or shortness of breath after collection, seek emergency care.

Patient FAQ & Clinical Guidance

1. What is the FLT3 gene mutation quantitative monitoring test and why is it needed?

Snippet: The FLT3 quantitative mutation test measures the percentage of leukemic cells carrying FLT3‑ITD or TKD mutations to assess minimal residual disease and guide targeted therapy decisions.

This highly sensitive assay detects and quantifies the abnormal gene copies in your blood or bone marrow, enabling your oncologist to track response to treatment and detect early relapse. The test is performed using Real‑Time PCR, which can identify one mutated cell among 10,000 normal cells. Regular monitoring is crucial for acute myeloid leukemia patients receiving FLT3 inhibitors.

2. How does this test help in leukemia treatment monitoring?

Snippet: Serial quantitative monitoring of FLT3 mutation burden allows dynamic risk stratification and timely intervention, significantly improving progression‑free survival in FLT3‑mutated AML.

By comparing mutation levels before, during, and after therapy, hematologists can identify molecular remission or resistance. A rising FLT3 level may prompt a change in drug dosage or combination therapy, while a sustained negative result reassures continued response. The test integrates with MRD (minimal residual disease) protocols, offering a non‑invasive window into disease activity.

3. What are the sample requirements and how quickly will I receive the result?

Snippet: A 5 mL whole blood or bone marrow sample in an EDTA lavender‑top tube, shipped refrigerated and never frozen, is required; results are delivered by Saturday if collected by Thursday 11 AM.

A duly filled MRD Requisition Form (Form 22) with complete historical data is mandatory. Home phlebotomy for whole blood is available daily from 8 AM to 11 PM. Bone marrow aspiration must be performed in an accredited hospital. Samples are accepted only on Monday and Thursday before 11 AM, with corresponding reports on Wednesday and Saturday. Do not freeze the sample under any circumstances—refrigerated transport maintains sample integrity.

UAE Regulatory & Data Privacy Adherence

Your health data is protected under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under DHA Facility License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. ISO 9001:2015 Certified (INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	FLT3 Gene Mutation Quantitative Monitoring
Price (AED)	650
Turnaround Time	48–72 hours post‑collection; reports on Wednesday or Saturday
Sample Type / Matrix	Peripheral Whole Blood (5 mL EDTA) – Home collection available; Bone Marrow aspirate – Hospital Only
Methodology Used	Real‑Time PCR (qPCR) with allelic discrimination, cross‑validated by Whole Genome Sequencing
ICD‑10‑CM Code	C92.62, Z51.81, C92.00
LOINC Code	82291‑1 (FLT3 gene targeted mutation analysis)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE